Roche has been presenting its plans for future growth to the investment community in New York and says it expects to launch at least six new products by 2015.

The Swiss giant’s late-stage pipeline comprises more than 35 additional indications for existing products and ten new molecular entities “that all offer the potential to be first- or best-in-class medicines”, Unsurprisingly, of those ten, five are cancer candidates – pertuzumab and T–DM1 for HER2-positive breast cancer, RG7204, a targeted BRAF inhibitor for malignant melanoma, GA101/RG7159, the first glyco-engineered humanised anti-CD20 monoclonal antibody for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma and RG3616 for the treatment of advanced basal cell carcinoma, and potentially other cancers such as colorectal cancer.

The others include taspoglutide for type 2 diabetes, dalcetrapib for dyslipidaemia and RG1678 to treat symptoms of schizophrenia. Chief executive Severin Schwan said Roche is “uniquely positioned to deliver sustainable, long-term growth”, claiming that the “seamless cooperation between our pharmaceuticals and diagnostics units from research through to the market” making personalised healthcare “an integral part of our drug development efforts.”